TearSolutions
$38.7Mtotal raised · 9 rounds on record
$517klatest round · Venture round · Oct 2025 · 12 mo ago
1backers · LaunchCapital
50+team · employees, estimated range
Overview
NATURAL THERAPY FOR OCULAR SURFACE DISEASE. TearSolutions has developed LacripepTM, a proprietary first-in-class peptide therapy.
Funding and backers
Total raised
$38.7M
9 rounds on record
Latest round
$517k
Venture round · Oct 2025 · 12 mo ago
Team
51-200
employees, estimated range
Backers
1
LaunchCapital
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 29, 2025
Raised a round Venture round $517k · SEC Form D
Sep 25, 2024
Raised a round Venture round $12.7M · SEC Form D
Apr 3, 2024
Board appointment TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors · YahooFinance
Oct 31, 2023
Board appointment TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors · markets.businessinsider.com
Sep 8, 2023
Raised a round Convertible Note $390k · SEC Form D
Jul 16, 2021
Raised a round Convertible Note $5.6M · SEC Form D
Feb 12, 2020
Raised a round Venture round $1.5M · SEC Form D
Mar 4, 2019
Raised a round Convertible Note $5.1M · SEC Form D
Mar 4, 2019
Raised a round Venture round $1.3M · SEC Form D
Dec 4, 2017
Raised a round Venture round $8.1M · SEC Form D
Jan 18, 2017
Raised a round Convertible Note $3.4M · SEC Form D
2015
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2025 | $517k | — | SEC Form D |
| Venture round | Sep 2024 | $12.7M | — | SEC Form D |
| Convertible Note | Sep 2023 | $390k | — | SEC Form D |
| Convertible Note | Jul 2021 | $5.6M | — | SEC Form D |
| Venture round | Feb 2020 | $1.5M | — | SEC Form D |
| Convertible Note | Mar 2019 | $5.1M | — | SEC Form D |
| Venture round | Mar 2019 | $1.3M | — | SEC Form D |
| Venture round | Dec 2017 | $8.1M | — | SEC Form D |
| Convertible Note | Jan 2017 | $3.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | TearSolutions, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Thomas GadekExecutive Officer, DirectorSEC Form D
Gordon LaurieExecutive OfficerSEC Form D
Mark LoganDirectorSEC Form D
Colin RolphExecutive OfficerSEC Form D
W. McIlwaine Thompson Jr.Executive OfficerSEC Form D
Tom GadekExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Kidaura
backs Celaid Therapeutics
Similar startupsby what they do, their industry and backers
Innerva Pharmaceuticals is an innovative ophthalmic startup developing novel therapies for ocular surface pain.
Physician-vetted peptide therapy, GLP-1 medications, and preventive care prescribed and shipped, if appropriate. 1:1 care, precisely for…
Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).
Dispensed is Australia's easiest to use online platform linking you to highly trained natural therapy doctors. Book a FREE consultation…
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
ITsavvy provides best-in-class IT solutions, so you can focus on what’s most mission-critical for your business. See the ITsavvy difference…
Financials
Total raised
$38.7M
Latest round
Venture - Series Unknown
Funding rounds
9
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $517k | Details |
| Venture - Series Unknown | 2024 | $12.7M | Details |
| Convertible Note | 2023 | $390k | Details |
| Convertible Note | 2021 | $5.6M | Details |
| Venture - Series Unknown | 2020 | $1.5M | Details |
| Convertible Note | 2019 | $5.1M | Details |
| Venture - Series Unknown | 2019 | $1.3M | Details |
| Venture - Series Unknown | 2017 | $8.1M | Details |
| Convertible Note | 2017 | $3.4M | Details |
People
Thomas Gadek
Executive Officer, Director
Gordon Laurie
Executive Officer
Mark Logan
Director
Colin Rolph
Executive Officer
W. McIlwaine Thompson Jr.
Executive Officer
Tom Gadek
Executive Officer, Director
Marc Odrich
Executive Officer
Michelle Carpenter
Executive Officer
John Moore
Executive Officer
William Thompson Jr.
Executive Officer
Anil Asrani
Executive Officer, Director
Laurie Gordon
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
LaunchCapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed
Read more
Report
TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors
Dr. Alpern brings extensive clinical trialing experience in ophthalmologyCHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Ey
Read more
Report
Our Solution - LacripepTM
The co-founder discovered 'lacritin', a natural tear protein selectively deficient in dry eye and yet when added topically to eyes of dry eye animals restores basal tearing without irritation and homeostasis of the eye surface. TearSolutions has developed
Read more
Report
Dry Eye Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer quis diam et magna pretium convallis. Ut tempor tellus vitae tortor tincidunt viverra. Sed pharetra eget diam quis tincidunt. Aenean euismod semper nunc, eu consequat arcu pharetra in. Nulla
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Charlottesville
United States
HQ
50-200 est. staff